Over the next 5 years, the NOSEVAC consortium will work intensively to create nasal vaccines targeting S. pneumoniae and B. pertussis infections. On top of that, they will develop a bivalent nasal vaccine to simultaneously prevent influenza and COVID-19.
June 2023
Bacterial and viral respiratory infections are significant contributors to global morbidity and mortality. Streptococcus pneumoniae and Bordetella pertussis, along with influenza virus and SARS-CoV-2, are causative agents of respiratory diseases that have substantial public health implications; acquired pneumonia, whooping cough, influenza, and COVID-19, respectively. The available vaccines against these diseases are administered via intramuscular or subcutaneous injection, and do not effectively prevent colonisation or infection of the upper respiratory tract (URT). Consequently, their impact on pathogen transmission is limited.
The NOSEVAC consortium, operating under the coordination of the European Vaccine Initiative (EVI), endeavours to cultivate and evaluate inventive nasal vaccine platforms as a ground-breaking approach to prevent the earliest stage of infection, thereby inhibiting URT colonisation, transmission, and disease. The project relies upon a distinctive consortium comprising 12 distinguished and complementary research teams hailing from the European Union (EU), UK and Switzerland.
Funding from the EU, the UK and Swiss governments allowed the project launch which, in addition to develop new nasal vaccine candidates, will:
• Develop vaccine formulations for nasal delivery of RNA- and protein-based antigens
• Discover bacterial antigens that promote colonisation of the URT
• Identify human host immune factors for long-term protection of the URT
• Address acceptability of nasal vaccination
It is expected that NOSEVAC will establish strategic research pathways to combat respiratory pathogens, encompassing those with the potential for large outbreaks. Furthermore, the organisation will serve as a catalyst for evidence-driven decision-making for policymakers and investors.
----
Quick facts about NOSEVAC:
Project full name: Innovative nasal vaccines to prevent pathogen colonization and infection in the upper respiratory tract.
Duration: 5 years (01 May 2023-30 April 2028)
Funding agency: European Commission
Budget: 11.1 € (with 6.8 Mio from EU)
Coordinator: European Vaccine Initiative (EVI)
Consortium: 12 partners (from 6 EU countries + UK+ Switzerland)
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.
Contact:
Project Manager: Monika Ślęzak, PhD
NOSEVAC partners:
PROJECT COORDINATOR
PROJECT PARTNERS:
Erasmus MC - department of Viroscience
Comments